Which has better valuation and earnings, AARD or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aardvark Therapeutics N/A N/A -$57.59M -$3.21 N/A Alterity Therapeutics N/A N/A -$15.89M N/A N/A

Is AARD or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Aardvark Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Aardvark Therapeutics N/A -71.54% -64.94% Alterity Therapeutics N/A N/A N/A

Which has higher earnings & valuation, NRXP or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than NRx Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NRx Pharmaceuticals $1.23M 122.51 -$28.62M -$0.55 N/A Alterity Therapeutics N/A N/A -$15.89M N/A N/A

Is NRXP or ATHE more profitable?

Alterity Therapeutics has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%. Company Net Margins Return on Equity Return on Assets NRx Pharmaceuticals -691.81% N/A -63.92% Alterity Therapeutics N/A N/A N/A

Which has higher earnings & valuation, UNCY or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than Unicycive Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Unicycive Therapeutics $680K 212.97 -$26.56M -$1.75 N/A Alterity Therapeutics N/A N/A -$15.89M N/A N/A

Is UNCY or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Unicycive Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Unicycive Therapeutics N/A -91.50% -61.47% Alterity Therapeutics N/A N/A N/A

Which has higher valuation & earnings, LENZ or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio LENZ Therapeutics $19.09M 8.58 -$82.13M -$4.09 N/A Alterity Therapeutics N/A N/A -$15.89M N/A N/A

Which has stronger earnings & valuation, VTVT or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than vTv Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio vTv Therapeutics $1.02M 123.61 -$26.97M -$1.06 N/A Alterity Therapeutics N/A N/A -$15.89M N/A N/A

Is VTVT or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat vTv Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets vTv Therapeutics N/A -6.27% -5.06% Alterity Therapeutics N/A N/A N/A

Alterity Therapeutics (ATHE) Competitors

$4.49 -0.02 (-0.44%)

As of 08/31/2026 04:00 PM Eastern

Compare

ATHE vs. AARD, NRXP, UNCY, LENZ, and VTVT

Should you buy Alterity Therapeutics stock or one of its competitors? Alterity Therapeutics's main competitors and comparable companies include Aardvark Therapeutics (AARD), NRx Pharmaceuticals (NRXP), Unicycive Therapeutics (UNCY), LENZ Therapeutics (LENZ), and vTv Therapeutics (VTVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Alterity Therapeutics compare to Aardvark Therapeutics?

Aardvark Therapeutics (NASDAQ:AARD) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, analyst recommendations, risk, media sentiment, dividends, earnings, institutional ownership and profitability.

Alterity Therapeutics' return on equity of 0.00% beat Aardvark Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aardvark Therapeutics	N/A	-71.54%	-64.94%
Alterity Therapeutics	N/A	N/A	N/A

Aardvark Therapeutics currently has a consensus price target of $15.33, suggesting a potential upside of 151.37%. Alterity Therapeutics has a consensus price target of $10.00, suggesting a potential upside of 122.72%. Given Aardvark Therapeutics' higher possible upside, equities analysts plainly believe Aardvark Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aardvark Therapeutics	2 Sell rating(s)	4 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.42
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Aardvark Therapeutics has a beta of 3.8, suggesting that its stock price is 280% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

In the previous week, Aardvark Therapeutics had 27 more articles in the media than Alterity Therapeutics. MarketBeat recorded 28 mentions for Aardvark Therapeutics and 1 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 1.89 beat Aardvark Therapeutics' score of 0.04 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aardvark Therapeutics	Neutral
Alterity Therapeutics	Very Positive

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aardvark Therapeutics	N/A	N/A	-$57.59M	-$3.21	N/A
Alterity Therapeutics	N/A	N/A	-$15.89M	N/A	N/A

2.1% of Alterity Therapeutics shares are held by institutional investors. 17.8% of Aardvark Therapeutics shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Alterity Therapeutics beats Aardvark Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Alterity Therapeutics compare to NRx Pharmaceuticals?

NRx Pharmaceuticals (NASDAQ:NRXP) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, earnings, institutional ownership, profitability, media sentiment and dividends.

4.3% of NRx Pharmaceuticals shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 6.4% of NRx Pharmaceuticals shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, NRx Pharmaceuticals had 17 more articles in the media than Alterity Therapeutics. MarketBeat recorded 18 mentions for NRx Pharmaceuticals and 1 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 1.89 beat NRx Pharmaceuticals' score of -0.30 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
NRx Pharmaceuticals	Neutral
Alterity Therapeutics	Very Positive

NRx Pharmaceuticals has a beta of 2.18, suggesting that its stock price is 118% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

NRx Pharmaceuticals presently has a consensus target price of $34.50, suggesting a potential upside of 891.38%. Alterity Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 122.72%. Given NRx Pharmaceuticals' higher possible upside, equities analysts clearly believe NRx Pharmaceuticals is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NRx Pharmaceuticals	2 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.43
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Alterity Therapeutics has a net margin of 0.00% compared to NRx Pharmaceuticals' net margin of -691.81%.

Company	Net Margins	Return on Equity	Return on Assets
NRx Pharmaceuticals	-691.81%	N/A	-63.92%
Alterity Therapeutics	N/A	N/A	N/A

Alterity Therapeutics has lower revenue, but higher earnings than NRx Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NRx Pharmaceuticals	$1.23M	122.51	-$28.62M	-$0.55	N/A
Alterity Therapeutics	N/A	N/A	-$15.89M	N/A	N/A

Summary

NRx Pharmaceuticals and Alterity Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Alterity Therapeutics compare to Unicycive Therapeutics?

Unicycive Therapeutics (NASDAQ:UNCY) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, media sentiment, analyst recommendations and institutional ownership.

Alterity Therapeutics' return on equity of 0.00% beat Unicycive Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Unicycive Therapeutics	N/A	-91.50%	-61.47%
Alterity Therapeutics	N/A	N/A	N/A

Unicycive Therapeutics has a beta of 1.79, indicating that its stock price is 79% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market.

Unicycive Therapeutics presently has a consensus price target of $18.75, indicating a potential upside of 260.58%. Alterity Therapeutics has a consensus price target of $10.00, indicating a potential upside of 122.72%. Given Unicycive Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Unicycive Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Unicycive Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

40.4% of Unicycive Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 6.0% of Unicycive Therapeutics shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Alterity Therapeutics has lower revenue, but higher earnings than Unicycive Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Unicycive Therapeutics	$680K	212.97	-$26.56M	-$1.75	N/A
Alterity Therapeutics	N/A	N/A	-$15.89M	N/A	N/A

In the previous week, Unicycive Therapeutics and Unicycive Therapeutics both had 1 articles in the media. Alterity Therapeutics' average media sentiment score of 1.89 beat Unicycive Therapeutics' score of 1.87 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Unicycive Therapeutics	Very Positive
Alterity Therapeutics	Very Positive

Summary

Unicycive Therapeutics beats Alterity Therapeutics on 6 of the 11 factors compared between the two stocks.

How does Alterity Therapeutics compare to LENZ Therapeutics?

LENZ Therapeutics (NASDAQ:LENZ) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Alterity Therapeutics has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -586.74%. Alterity Therapeutics' return on equity of 0.00% beat LENZ Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
LENZ Therapeutics	-586.74%	-53.39%	-49.14%
Alterity Therapeutics	N/A	N/A	N/A

54.3% of LENZ Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 8.3% of LENZ Therapeutics shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Alterity Therapeutics has lower revenue, but higher earnings than LENZ Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
LENZ Therapeutics	$19.09M	8.58	-$82.13M	-$4.09	N/A
Alterity Therapeutics	N/A	N/A	-$15.89M	N/A	N/A

In the previous week, LENZ Therapeutics had 5 more articles in the media than Alterity Therapeutics. MarketBeat recorded 6 mentions for LENZ Therapeutics and 1 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 1.89 beat LENZ Therapeutics' score of 1.15 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
LENZ Therapeutics	Positive
Alterity Therapeutics	Very Positive

LENZ Therapeutics presently has a consensus price target of $28.80, indicating a potential upside of 452.78%. Alterity Therapeutics has a consensus price target of $10.00, indicating a potential upside of 122.72%. Given LENZ Therapeutics' higher possible upside, equities research analysts clearly believe LENZ Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

LENZ Therapeutics has a beta of 0.65, meaning that its stock price is 35% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, meaning that its stock price is 73% less volatile than the broader market.

Summary

LENZ Therapeutics and Alterity Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

How does Alterity Therapeutics compare to vTv Therapeutics?

vTv Therapeutics (NASDAQ:VTVT) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership and valuation.

vTv Therapeutics has a beta of 0.29, suggesting that its stock price is 71% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.27, suggesting that its stock price is 73% less volatile than the broader market.

vTv Therapeutics currently has a consensus target price of $55.83, suggesting a potential upside of 74.48%. Alterity Therapeutics has a consensus target price of $10.00, suggesting a potential upside of 122.72%. Given Alterity Therapeutics' higher possible upside, analysts plainly believe Alterity Therapeutics is more favorable than vTv Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
vTv Therapeutics	2 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

Alterity Therapeutics' return on equity of 0.00% beat vTv Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
vTv Therapeutics	N/A	-6.27%	-5.06%
Alterity Therapeutics	N/A	N/A	N/A

17.5% of vTv Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 6.0% of vTv Therapeutics shares are held by company insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, vTv Therapeutics had 1 more articles in the media than Alterity Therapeutics. MarketBeat recorded 2 mentions for vTv Therapeutics and 1 mentions for Alterity Therapeutics. Alterity Therapeutics' average media sentiment score of 1.89 beat vTv Therapeutics' score of 0.94 indicating that Alterity Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
vTv Therapeutics	Positive
Alterity Therapeutics	Very Positive

Alterity Therapeutics has lower revenue, but higher earnings than vTv Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
vTv Therapeutics	$1.02M	123.61	-$26.97M	-$1.06	N/A
Alterity Therapeutics	N/A	N/A	-$15.89M	N/A	N/A

Summary

Alterity Therapeutics beats vTv Therapeutics on 6 of the 11 factors compared between the two stocks.

Get Alterity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHE vs. The Competition

Export

Metric	Alterity Therapeutics	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$39.99M	$12.19B	$7.20B	$12.89B
Dividend Yield	N/A	2.62%	2.54%	11.28%
P/E Ratio	N/A	785.16	272.59	25.48
Price / Sales	N/A	755.90	624.04	92.52
Price / Cash	N/A	15.32	28.74	36.03
Price / Book	1.45	10.48	11.05	6.34
Net Income	-$15.89M	$2.83B	$3.47B	$349.45M
7 Day Performance	0.45%	-0.94%	0.27%	-0.65%
1 Month Performance	1.81%	5.13%	8.28%	4.48%
1 Year Performance	-9.11%	5.97%	24.14%	14.89%

Alterity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHE Alterity Therapeutics	3.4824 of 5 stars	$4.49 -0.4%	$10.00 +122.7%	-9.1%	$39.99M	N/A	N/A	10	Gap Up
AARD Aardvark Therapeutics	2.8541 of 5 stars	$7.25 +5.4%	$16.30 +124.8%	-26.5%	$150.56M	N/A	N/A	18
NRXP NRx Pharmaceuticals	1.8752 of 5 stars	$3.67 +6.4%	$34.50 +840.1%	+50.0%	$149.37M	$1.23M	N/A	2
UNCY Unicycive Therapeutics	3.2072 of 5 stars	$5.47 +2.4%	$18.75 +242.8%	+24.1%	$148.75M	$680K	N/A	9	Positive News
LENZ LENZ Therapeutics	3.5536 of 5 stars	$4.67 +1.7%	$28.80 +516.7%	-86.5%	$144.22M	$19.09M	N/A	110	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHE) was last updated on 9/1/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alterity Therapeutics (ATHE) Competitors

ATHE vs. AARD, NRXP, UNCY, LENZ, and VTVT

How does Alterity Therapeutics compare to Aardvark Therapeutics?

Summary

How does Alterity Therapeutics compare to NRx Pharmaceuticals?

Summary

How does Alterity Therapeutics compare to Unicycive Therapeutics?

Summary

How does Alterity Therapeutics compare to LENZ Therapeutics?

Summary

How does Alterity Therapeutics compare to vTv Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alterity Therapeutics (ATHE) Competitors

ATHE vs. AARD, NRXP, UNCY, LENZ, and VTVT

How does Alterity Therapeutics compare to Aardvark Therapeutics?

Is AARD or ATHE more profitable?

Do analysts recommend AARD or ATHE?

Which has more volatility & risk, AARD or ATHE?

Does the media favor AARD or ATHE?

Which has better valuation and earnings, AARD or ATHE?

Do insiders & institutionals hold more shares of AARD or ATHE?

Summary

How does Alterity Therapeutics compare to NRx Pharmaceuticals?

Do institutionals and insiders hold more shares of NRXP or ATHE?

Does the media favor NRXP or ATHE?

Which has more volatility and risk, NRXP or ATHE?

Do analysts recommend NRXP or ATHE?

Is NRXP or ATHE more profitable?

Which has higher earnings & valuation, NRXP or ATHE?

Summary

How does Alterity Therapeutics compare to Unicycive Therapeutics?

Is UNCY or ATHE more profitable?

Which has more risk & volatility, UNCY or ATHE?

Do analysts prefer UNCY or ATHE?

Do institutionals & insiders have more ownership in UNCY or ATHE?

Which has higher earnings & valuation, UNCY or ATHE?

Does the media prefer UNCY or ATHE?

Summary

How does Alterity Therapeutics compare to LENZ Therapeutics?

Is LENZ or ATHE more profitable?

Do institutionals & insiders believe in LENZ or ATHE?

Which has higher valuation & earnings, LENZ or ATHE?

Does the media refer more to LENZ or ATHE?

Do analysts rate LENZ or ATHE?

Which has more risk & volatility, LENZ or ATHE?

Summary

How does Alterity Therapeutics compare to vTv Therapeutics?

Which has more volatility and risk, VTVT or ATHE?

Do analysts recommend VTVT or ATHE?

Is VTVT or ATHE more profitable?

Do institutionals and insiders hold more shares of VTVT or ATHE?

Does the media prefer VTVT or ATHE?

Which has stronger earnings & valuation, VTVT or ATHE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools